123 related articles for article (PubMed ID: 26531748)
21. The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer.
Zhang W; Tian X; Mumtahana F; Jiao J; Zhang T; Croce KD; Ma D; Kong B; Cui B
BMC Cancer; 2015 Oct; 15():717. PubMed ID: 26474968
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology.
Liu Y; Lu Z; Xu R; Ke Y
Oncotarget; 2016 Feb; 7(5):5852-64. PubMed ID: 26735580
[TBL] [Abstract][Full Text] [Related]
23. The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis.
Kim ST; Lee J; Hong M; Park K; Park JO; Ahn T; Park SH; Park YS; Lim HY; Sun JM; Ahn JS; Ahn MJ; Kim HC; Sohn TS; Choi DI; Cho JH; Heo JS; Kwon W; Uhm SW; Lee H; Min BH; Hong SN; Kim DH; Jung SH; Park W; Kim KM; Kang WK; Park K
Oncotarget; 2015 Oct; 6(32):33358-68. PubMed ID: 26396172
[TBL] [Abstract][Full Text] [Related]
24. Chromosomal instability as a prognostic marker in cervical cancer.
How C; Bruce J; So J; Pintilie M; Haibe-Kains B; Hui A; Clarke BA; Hedley DW; Hill RP; Milosevic M; Fyles A; Liu FF
BMC Cancer; 2015 May; 15():361. PubMed ID: 25944123
[TBL] [Abstract][Full Text] [Related]
25. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
26. Rapid detection of genetic mutations in individual breast cancer patients by next-generation DNA sequencing.
Liu S; Wang H; Zhang L; Tang C; Jones L; Ye H; Ban L; Wang A; Liu Z; Lou F; Zhang D; Sun H; Dong H; Zhang G; Dong Z; Guo B; Yan H; Yan C; Wang L; Su Z; Li Y; Huang XF; Chen SY; Zhou T
Hum Genomics; 2015 Feb; 9(1):2. PubMed ID: 25757876
[TBL] [Abstract][Full Text] [Related]
27. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
28. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
[TBL] [Abstract][Full Text] [Related]
29. SCC-Ag, lymph node metastases and sentinel node procedure in early stage squamous cell cervical cancer.
van de Lande J; Davelaar EM; von Mensdorff-Pouilly S; Water TJ; Berkhof J; van Baal WM; Kenemans P; Verheijen RH
Gynecol Oncol; 2009 Jan; 112(1):119-25. PubMed ID: 19007978
[TBL] [Abstract][Full Text] [Related]
30. Detecting cytokeratin 19 mRNA in the peripheral blood cells of cervical cancer patients and its clinical-pathological correlation.
Yuan CC; Wang PH; Ng HT; Li YF; Huang TS; Chen CY; Tsai LC; Shyong WY
Gynecol Oncol; 2002 Apr; 85(1):148-53. PubMed ID: 11925135
[TBL] [Abstract][Full Text] [Related]
31. The use of personalized biomarkers and liquid biopsies to monitor treatment response and disease recurrence in locally advanced rectal cancer after neoadjuvant chemoradiation.
Carpinetti P; Donnard E; Bettoni F; Asprino P; Koyama F; Rozanski A; Sabbaga J; Habr-Gama A; Parmigiani RB; Galante PA; Perez RO; Camargo AA
Oncotarget; 2015 Nov; 6(35):38360-71. PubMed ID: 26451609
[TBL] [Abstract][Full Text] [Related]
32. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
Hyman DM; Solit DB; Arcila ME; Cheng DT; Sabbatini P; Baselga J; Berger MF; Ladanyi M
Drug Discov Today; 2015 Dec; 20(12):1422-8. PubMed ID: 26320725
[TBL] [Abstract][Full Text] [Related]
33. Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.
Yin FF; Wang N; Bi XN; Yu X; Xu XH; Wang YL; Zhao CQ; Luo B; Wang YK
Virol J; 2016 Apr; 13():60. PubMed ID: 27044426
[TBL] [Abstract][Full Text] [Related]
34. Loss of MSH2 protein expression is a risk factor in early stage cervical cancer.
Nijhuis ER; Nijman HW; Oien KA; Bell A; ten Hoor KA; Reesink-Peters N; Boezen HM; Hollema H; van der Zee AG
J Clin Pathol; 2007 Jul; 60(7):824-30. PubMed ID: 17596548
[TBL] [Abstract][Full Text] [Related]
35. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
36. Wnt signalling in gynaecological cancers: A future target for personalised medicine?
Ford CE; Henry C; Llamosas E; Djordjevic A; Hacker N
Gynecol Oncol; 2016 Feb; 140(2):345-51. PubMed ID: 26432042
[TBL] [Abstract][Full Text] [Related]
37. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
38. Clinicopathological and prognostic significance of Bmi-1 expression in human cervical cancer.
Min L; Dong-Xiang S; Xiao-Tong G; Ting G; Xiao-Dong C
Acta Obstet Gynecol Scand; 2011 Jul; 90(7):737-45. PubMed ID: 21309753
[TBL] [Abstract][Full Text] [Related]
39. Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer.
Lin PH; Kuo WH; Huang AC; Lu YS; Lin CH; Kuo SH; Wang MY; Liu CY; Cheng FT; Yeh MH; Li HY; Yang YH; Hsu YH; Fan SC; Li LY; Yu SL; Chang KJ; Chen PL; Ni YH; Huang CS
Oncotarget; 2016 Feb; 7(7):8310-20. PubMed ID: 26824983
[TBL] [Abstract][Full Text] [Related]
40. Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.
Park YH; Shin HT; Jung HH; Choi YL; Ahn T; Park K; Lee A; Do IG; Kim JY; Ahn JS; Park WY; Im YH
Oncotarget; 2015 Oct; 6(31):32027-38. PubMed ID: 26397225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
